PsychoGenics Achieves Top Supplier Status on Scientist.com for 2023
PGI is pleased to be recognized by scientist.com as a top marketplace supplier for 2023.
PsychoGenics Announces Exclusive Global License for an IND-ready ENT1 Inhibitor for the Treatment of Neuropsychiatric Disorders
PGI Drug Discovery LLC (PsychoGenics), a phenotypic drug discovery platform company, announced that it has entered into an exclusive license agreement with Roche to obtain global development, manufacturing, and commercialization rights…
PsychoGenics Launches Updated Corporate Identity and Brand
PsychoGenics, Inc. (“PsychoGenics” or the “Company”), the leading contract research organization (CRO) specializing in the central nervous system (CNS) focused preclinical and translational drug discovery services, is proud to unveil…
How AI Will Make Our Lives Better (And Worse)
May 31, 2023・By David H. Freedman・Newsweek Magazine The explosion of progress in artificial intelligence in recent months has surprised even...
AI-discovered drug shows ‘enormous potential’ to treat schizophrenia: ‘Real need for better treatment’
May 9, 2023・By Angelica Stabile・Fox News PsychoGenics CEO reveals how machine learning has enabled new steps toward addressing mental disorder As...
PsychoGenics Launches eCube, a New AI-Enabled Platform for Drug Discovery
April 6, 2023・Businesswire PARAMUS, N.J.–(BUSINESS WIRE)–PsychoGenics Inc. (“PsychoGenics” or the “Company”), a leader in AI-enabled phenotypic drug discovery and preclinical CRO...